| An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy (NCT07238868) | Shanghai Zhimeng Biopharma, Inc. | 2025-08-14 |
| A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB (NCT07095855) | Shanghai Zhimeng Biopharma, Inc. | 2025-08-01 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy (NCT06612775) | Shanghai Zhimeng Biopharma, Inc. | 2024-09-01 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB06-036 in Subjects With Chronic Hepatitis B (NCT05828745) | Shanghai Zhimeng Biopharma, Inc. | 2024-04-22 |
| A Bridging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB06-036 in Healthy Subjects in China (NCT06101316) | Shanghai Zhimeng Biopharma, Inc. | 2023-09-19 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants in Australia (NCT05502549) | Shanghai Zhimeng Biopharma, Inc. | 2022-11-29 |
| A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patients With CHB (NCT05484466) | Shanghai Zhimeng Biopharma, Inc. | 2022-11-11 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants (NCT05499260) | Shanghai Zhimeng Biopharma, Inc. | 2022-05-02 |
| A Multiple-dose Study in Chinese Subjects to Evaluate Safety,Tolerability,PK and PD of ZM-H1505R (NCT05470829) | Shanghai Zhimeng Biopharma, Inc. | 2021-05-27 |
| A Study of Orally Administered ZM-H1505R to Evaluate Safety, Tolerability and Pharmacokinetics After Single and Multiple Ascending Doses in Healthy Participants (NCT04220801) | Shanghai Zhimeng Biopharma, Inc. | 2020-02-17 |